Abstract:Diseases caused by human herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) affect millions of people worldwide and range from fatal encephalitis in neonates and herpes keratitis to orofacial and genital herpes, among other manifestations. The viruses can be shed efficiently by asymptomatic carriers, causing increased rates of infection. Viral transmission occurs through direct contact of mucosal surfaces followed by initial replication of the incoming virus in skin tissues. Subsequently, the viruses infect sensory neurons in the trigeminal and lumbosacral dorsal root ganglia, where they are primarily maintained in a transcriptionally repressed state termed "latency", which persists for the lifetime of the host. HSV DNA has also been detected in other sympathetic ganglia. Periodically, latent viruses can reactivate, causing ulcerative and often painful lesions primarily at the site of primary infection and proximal sites. In the United States, recurrent genital herpes alone accounts for more than a billion dollars in direct medical costs per year, while there are much higher costs associated with the socio-economic aspects of diseased patients, such as loss of productivity due to mental anguish. Currently, there are no effective FDA-approved vaccines for either prophylactic or therapeutic treatment of human herpes simplex infections, while several recent clinical trials have failed to achieve their endpoint goals. Historically, live-attenuated vaccines have successfully combated viral diseases, including polio, influenza, measles, and smallpox. Vaccines aimed to protect against the devastation of smallpox led to the most significant achievement in medical history: the eradication of human disease by vaccination. Recently, novel approaches toward developing safe and effective live-attenuated vaccines have demonstrated high efficacy in various preclinical models of herpetic disease. This next generation of live-attenuated vaccines has been tailored to minimize vaccine-associated side effects and promote effective and long-lasting immune responses. The ultimate goal is to prevent or reduce primary infections (prophylactic vaccines) or reduce the frequency and severity of disease associated with reactivation events (therapeutic vaccines). These vaccines' "rational" design is based on our current understanding of the immunopathogenesis of herpesviral infections that guide the development of vaccines that generate robust and protective immune responses. This review covers recent advances in the development of herpes simplex vaccines and the current state of ongoing clinical trials in pursuit of an effective vaccine against herpes simplex virus infections and associated diseases.

The Quest for Immunity: Exploring Human Herpesviruses as Vaccine Vectors

Utilization of herpesviridae as recombinant viral vectors in vaccine development against animal pathogens

New viral vectors for infectious diseases and cancer

A review of HSV pathogenesis, vaccine development, and advanced applications

Immune Response to Herpes Simplex Virus Infection and Vaccine Development

Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond

Viral and bacterial vectors of immunogenes

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

Molecular genetics of herpesviruses: a recombinant technology approach.

HHi-FiVe: A high-fidelity genetic engineering pipeline for construction of herpesvirus-based vaccines

Deriving Immune Modulating Drugs from Viruses—A New Class of Biologics

Development of Baculovirus as Vaccine Vectors

Advances in the immunoescape mechanisms exploited by alphaherpesviruses

Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses

Bacterial-Artificial-Chromosome-Based Genome Editing Methods and the Applications in Herpesvirus Research

Status Quo of the Researches on HSV Vaccines

Recent Advances in the Study of Alphaherpesvirus Latency and Reactivation: Novel Guidance for the Design of Herpesvirus Live Vector Vaccines

Integrating pan-genome and reverse vaccinology to design multi-epitope vaccine against Herpes simplex virus type-1

Non-replicative herpes simplex virus genomic and amplicon vectors for gene therapy - an update

Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents

Revolutionizing Veterinary Health with Viral Vector-Based Vaccines